Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies for gastrointestinal diseases, today announced the publication of additional results from ...
PureTech Health (PRTC) noted that its founded entity, Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia ...
Biosciences' lead drug candidate, VE303, has been reported to demonstrate efficacy in preventing recurrent Clostridioides ...
Skanska has signed a contract with Texas A&M University System to construct the new Meat Science and Technology Center on their campus in College Station, Texas, USA. The contract is worth USD 91M, ...
19h
Topline data for the ongoing Phase 3 pivotal RESTORATiVE303 study are expected in 2026 ...
* Terms and Conditions apply. Finance is subject to status. Applications must be a minimum age of 18. A guarantee may be ...
In a challenging year for biotechnology firms, PureTech Health PLC (PRTC) stock has touched a 52-week low, dipping to $16.81.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback